pharma · Unresectable Hepatocellular Carcinoma (HCC) · Unexplained Recurrent Miscarriage and Recurrent Implantation Failure
Zenshine Pharmaceuticals
Nanjing Zenshine Pharmaceuticals
Nanjing Zenshine Pharmaceuticals is a pharma organization headquartered in CN. Primary therapeutic focus areas include Unresectable Hepatocellular Carcinoma (HCC), Unexplained Recurrent Miscarriage and Recurrent Implanta
CN HQ
2018 Founded
12 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Founded
- 2018
- Employees
- 12
- Programs
- 8
- Drugs
- 17
- Patents
- 0
Camrelizumab Plus Apatinib
Phase 2 · small molecule · Unresectable Hepatocellular Carcinoma (HCC)
Camrelizumab Plus Apatinib for Unresectable Hepatocellular Carcinoma (HCC) is a Phase 2 program (small_molecule) at Nanjing Zenshine Pharmaceuticals with 1 ClinicalTrials.gov record(s).
Internal code FAD-HCC-001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Nanjing Zenshine Pharmaceuticals
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Unresectable Hepatocellular Carcinoma (HCC)
- Status
- active
- Trials
- 1